Thus, the benefit of communicating individual BRCA1/2 research results with patients who already have ovarian cancer, with respect to the risk of developing further BRCA-related cancers, is unclear and did not overcome the issues described below. This evidence concerns the gene BRCA1 and ovarian cancer.